บูคินซา

• ZANUBRUTINIB80.0 milligramต่อ 1 capsule

ประเภทควบคุม

ยาควบคุมพิเศษ

ข้อบ่งใช้

Mantle cell lymphoma (MCL) Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Waldenström’s Macroglobulinemia (WM) Zanubrutinib is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). Marginal Zone Lymphoma Zanubrutinib is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy. Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Zanubrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Follicular Lymphoma (FL) Zanubrutinib in combination with obinutuzumab is indicated for the treatment of adult patients with follicular lymphoma (FL) who have received at least 2 prior therapies.

รหัส ATC

L01EL03 (zanubrutinib)

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ